Literature DB >> 28279040

[Detection and analysis of plasma VWF levels in healthy Chinese by automatic standardized assay].

P Zhang1, Z Q Yu, X H Zhang, W Zhang, X Bai, L J Cao, J Su, P P Sha, Z Y Wang, C G Ruan.   

Abstract

Objective: To explore the normal range of plasma VWF levels of healthy Chinese and to analyze the influencing factors to VWF level.
Methods: To detect the levels of von Willebrand factor antigen (VWF∶Ag) , von Willebrand factor ristocetin cofactor activity (VWF∶Rco) , von Willebrand factor collagen binding activity (VWF∶CB) , and the factor Ⅷ coagulation activity (FⅧ∶C) by using fully automatic and standardized testing instruments and matching reagent in 70 healthy Chinese. The effects of age, ABO blood type, gender and region were also analyzed. Meanwhile, 8 standard plasma samples (2 normal subjects, 6 cases of type 2 VWD) confirmed by NIBSC were tested for VWF values.
Results: ① In 70 cases of healthy Chinese, the mean value of plasma VWF∶Ag, VWF∶Rco and VWF∶CB were (95.4±44.9) %, (105.9±35.4) % and (89.8±28.4) %, respectively; the ratio of VWF∶Rco/VWF∶Ag and VWF∶CB/VWF∶Ag was 1.18±0.25 and 1.03±0.29, respectively. ②There was no statistical significance in plasma VWF values between the age ≥30 years and <30 years group (P>0.05) . ③The VWF∶Rco, VWF∶CB of type O blood group were lower than that of non-O group (t=2.074, P=0.042; t=3.949, P=0.001) , but there was no statistical significance in VWF∶Ag, VWF∶Rco/VWF∶Ag, VWF∶CB/VWF∶Ag between the two groups (P>0.05) . ④There was no significant difference in VWF values between male and female groups (P>0.05) . ⑤The VWF∶Ag, VWF∶CB of the northern population (North area of Huaihe River) group were higher than that of southern population (Suzhou area) group (t=4.525, P=0.001; t=3.214, P=0.002) , but VWF∶Rco/VWF∶Ag, VWF∶CB/VWF∶Ag were lower than that of southern population group (t=6.373, P=0.001; t=2.902, P=0.005) , and there was no significant difference in VWF∶Rco between the two groups (t=1.598, P=0.115) . ⑥The VWF values of 8 standard plasma samples were in accordance with the known diagnosis. Conclusions: A more integrate plasma VWF levels of healthy Chinese people were obtained for the first time by using fully automatic and standardized testing instruments. It was also found that ABO blood group and region had a significant impact on the level of VWF, while the age and gender had no significant effect.

Entities:  

Keywords:  ABO blood-group system; Reference values; Sex factors; von Willebrand diseases; von Willebrand factor

Mesh:

Substances:

Year:  2017        PMID: 28279040      PMCID: PMC7354177          DOI: 10.3760/cma.j.issn.0253-2727.2017.02.012

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


血管性血友病因子(VWF)是一种由血管内皮细胞和骨髓巨核细胞合成的多聚化糖蛋白,介导血小板的黏附、聚集,并可保护血循环中的凝血因子Ⅷ(FⅧ)[1]。血浆VWF抗原(VWF∶Ag)和活性水平受年龄、种族、ABO血型、生理性应激、炎症等多种因素影响[2]–[5]。VWF∶Ag和活性水平检测项目较多且多为手工操作,检测结果存在较大的室内、室间差异,目前国内多数医院不能全面开展VWF相关检测,限制了血管性血友病(VWD)临床筛查的开展和诊断水平的提高。本研究中我们采用全自动、标准化VWF抗原和活性检测方法对正常人的VWF∶Ag和活性进行检测,并比较不同ABO血型、年龄、性别、地域(南方/北方)正常人血浆VWF水平,探寻中国人VWF的正常值范围。

材料与方法

一、研究对象 正常人外周静脉血标本来自于70名健康志愿者,39名来自苏州地区(南方组),31名来自淮河以北地区(北方组)。入组时间:2015年4月1日至2015年12月30日。排除标准:炎症、肿瘤、感染、应激、妊娠、内分泌系统疾病、心脑血管疾病、出凝血疾病等。O型血34名,非O型血36名;男女比例为1∶1;中位年龄30(21~53)岁。所有受试者均被详细告知试验流程并签署知情同意书。 二、主要试剂与仪器 HRP-兔抗人VWF多抗为丹麦Dako公司产品,ECL显影液为上海普飞生物技术有限公司产品,蛋白电泳夹心式垂直电泳槽为美国Bio-Rad公司产品,全自动凝血测定仪ACL-TOP和ACL-ACUSTAR及配套试剂为西班牙沃芬公司产品。 三、样本制备 空腹安静状态下采集受试者外周静脉血,以0.106 mol/L枸橼酸钠1∶9抗凝。抗凝血以1 610×g离心10 min,取乏血小板血浆分装冻存于−80 °C冰箱备用。 四、检测方法 采用沃芬公司的全自动、标准化检测仪器ACL-ACUSTAR和ACL-TOP及相应配套试剂进行血浆VWF∶Ag、血浆VWF瑞斯托霉素辅因子活性(VWF∶Rco)、VWF胶原结合试验(VWF∶CB)、FⅧ活性(FⅧ∶C)测定,按照仪器和试剂使用说明书操作。 五、标准血浆的测定 选择经英国国家生物标准与检定所(NIBSC)确认的2份正常人及6份2型VWD冻干血浆样本(随机编号1~8)加入本研究中的检测中。VWD诊断参考ISTH-SSC VWD委员会推荐标准[6]–[7]。 六、VWF多聚体分析 标准血浆的VWF多聚体分析采用琼脂糖凝胶垂直电泳方法,干胶后与抗VWF多克隆抗体反应,以酶化学发光反应显示区带,观察凝胶中不同分子量大小的VWF多聚体分布情况。具体步骤为:配制1.3%琼脂糖凝胶,缓冲体系:50 mmol/L Tris,400 mmol/L甘氨酸,0.1% SDS,30%丙三醇,pH 8.3。电泳缓冲液为1×Tris/甘氨酸/SDS(25 mmol/L Tris,192 mmol/L甘氨酸,0.1% SDS,pH 8.3)。待测血浆以样品稀释缓冲液(0.5 mol/L Tris-HCl,0.5 mol/L EDTA,0.1% SDS,9 mol/L Urea,pH 6.8)进行l∶39稀释。60 °C孵育30 min后上样(6 µl/孔)。4 °C下110 V恒压电泳3 h。电泳结束后,去离子水洗涤2次(每次10 min),将凝胶置于Gel Bond支撑膜上风干过夜。50 g/L脱脂奶粉-TBS室温封闭2 h。用0.1% TBST洗膜2次(每次5 min),加入1∶1 000的VWF多克隆抗体孵育1 h,0.1% TBST洗涤3次(每次20 min),ECL显影。 七、统计学处理 数据采用SPSS19.0软件进行统计学分析,两组间均数比较采用独立样本的t检验。以双侧P<0.05为差异有统计学意义。

结果

1.正常人血浆VWF相关指标检测结果:70名正常人血浆VWF∶Ag为(95.4±44.9)%,血浆VWF∶Rco为(105.9±35.4)%,VWF∶CB为(89.8±28.4)%,VWF∶Rco/VWF∶Ag比值为1.18±0.25,VWF∶CB/VWF∶Ag比值为1.03±0.29,VWF∶Ag、VWF∶Rco、VWF∶CB的最低值分别为36.2%、42.0%、46.1%,VWF∶Rco/VWF∶Ag和VWF∶CB/VWF∶Ag比值的最低值分别为0.63、0.54;其中VWF∶Rco/VWF∶Ag比值均未见<0.6,而VWF∶CB/VWF∶Ag比值在3名正常人中<0.6。详见表1。
表1

70名正常人血浆血管性血友病因子(VWF)相关指标检测结果

检测项目例数检测结果(x±s最低值
VWF∶Ag(%)7095.4±44.936.2
VWF∶Rco(%)70105.9±35.442.0
VWF∶CB(%)7089.8±28.446.1
VWF∶Rco/VWF∶Ag701.18±0.250.63
VWF∶CB/VWF∶Ag701.03±0.290.54

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验 2.血浆VWF水平与年龄的关系:本组70名正常人中位年龄为30岁,以此为界分为两组。年龄<30岁组与≥30岁组VWF∶Ag、VWF∶Rco、VWF∶CB、VWF∶Rco/VWF∶Ag、VWF∶CB/VWF∶Ag差异均无统计学意义(P>0.05)。详见表2。
表2

年龄对正常人血浆血管性血友病因子(VWF)水平的影响(±s)

组别例数VWF∶Ag(%)VWF∶Rco(%)VWF∶CB(%)VWF∶Rco/VWF∶AgVWF∶CB/VWF∶Ag
<30岁3390.3±49.0103.5±37.387.1±30.71.22±0.241.06±0.31
≥30岁37100.0±41.1108.1±34.092.2±26.31.14±0.261.00±0.27

t0.9020.5340.7411.2990.883
P0.3700.5950.4610.1980.380

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验 3.血浆VWF水平与ABO血型的关系:O型血VWF∶Rco、VWF∶CB低于非O型血组(t=2.074,P=0.042;t=3.949,P=0.001),VWF∶Ag、VWF∶Rco/VWF∶Ag、VWF∶CB/VWF∶Ag比值差异无统计学意义(P>0.05)。详见表3。
表3

ABO血型对正常人血浆血管性血友病因子(VWF)水平的影响(±s)

组别例数VWF∶Ag(%)VWF∶Rco(%)VWF∶CB(%)VWF∶Rco/VWF∶AgVWF∶CB/VWF∶Ag
O型血3488.7±50.697.1±36.277.3±26.51.18±0.240.97±0.29
非O型血36101.8±38.4114.3±33.1101.6±25.01.19±0.271.08±0.29

t1.2242.0743.9490.1401.505
P0.2250.0420.0010.8890.137

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验 4.血浆VWF水平与性别的关系:男性组与女性组比较,VWF∶Ag、VWF∶Rco、VWF∶CB、VWF∶Rco/VWF∶Ag、VWF∶CB/VWF∶Ag差异均无统计学意义(P>0.05)。详见表4。
表4

性别对正常人血浆血管性血友病因子(VWF)水平的影响(±s)

组别例数VWF∶Ag(%)VWF∶Rco(%)VWF∶CB(%)VWF∶Rco/VWF∶AgVWF∶CB/VWF∶Ag
男性3593.7±42.5105.1±37.784.3±27.61.19±0.240.98±0.29
女性3597.1±47.7106.8±33.595.2±28.51.18±0.261.07±0.28

t0.3170.2021.6240.0941.280
P0.7520.840.1090.9250.205

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验 5.血浆VWF水平与地域的关系:北方组VWF∶Ag、VWF∶CB高于南方组(t=4.525,P=0.001;t=3.214,P=0.002),VWF∶Rco/VWF∶Ag、VWF∶CB/VWF∶Ag比值均低于南方组(t=6.373,P=0.001;t=2.902,P=0.005),VWF∶Rco差异无统计学意义(P>0.05)。详见表5。
表5

不同地域正常人血浆血管性血友病因子(VWF)水平比较(±s)

组别例数VWF∶Ag(%)VWF∶Rco(%)VWF∶CB(%)VWF∶Rco/VWF∶AgVWF∶CB/VWF∶Ag
北方31119.5±50.6113.4±33.8101.3±26.31.01±0.240.92±0.25
南方3976.3±28.1100.0±36.080.7±26.91.32±0.161.11±0.29

t4.5251.5983.2146.3732.902
P0.0010.1150.0020.0010.005

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验 6.ABO血型对男性VWF相关指标的影响:男性O型血组VWF∶CB低于非O型血组(t=3.396,P=0.002),VWF∶Ag、VWF∶Rco、VWF∶Rco/VWF∶Ag、VWF∶CB/VWF∶Ag差异无统计学意义(P>0.05)。详见表6。
表6

ABO血型对男性正常人血浆血管性血友病因子(VWF)水平的影响(±s)

组别例数VWF∶Ag(%)VWF∶Rco(%)VWF∶CB(%)VWF∶Rco/VWF∶AgVWF∶CB/VWF∶Ag
男性O型血1880.4±33.097.0±35.070.9±20.61.23±0.150.96±0.28
男性非O型血17107.8±47.7113.7±39.598.6±27.41.13±0.311.01±0.32

t1.9821.3253.3961.2000.571
P0.0560.1940.0020.2390.572

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验 7.ABO血型对女性VWF相关指标的影响:女性O型血组VWF∶CB低于非O型血组(t=2.165,P=0.038),VWF∶Ag、VWF∶Rco、VWF∶Rco/VWF∶Ag、VWF∶CB/VWF∶Ag差异无统计学意义(P>0.05)。详见表7。
表7

ABO血型对女性正常人血浆血管性血友病因子(VWF)水平的影响(±s)

组别例数VWF∶Ag(%)VWF∶Rco(%)VWF∶CB(%)VWF∶Rco/VWF∶AgVWF∶CB/VWF∶Ag
女性O型血1698.0±65.097.3±38.684.5±31.11.12±0.301.00±0.30
女性非O型血1996.4±27.9114.8±27.1104.3±23.11.23±0.231.14±0.26

t0.0951.5752.1651.3141.484
P0.9250.1250.0380.1980.147

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验 8.不同地域O型血正常人血浆VWF水平比较:北方O型组正常人VWF∶Ag、VWF∶CB均高于南方O型组(t=4.600,P=0.001;t=4.340,P=0.001),VWF∶Rco/VWF∶Ag、VWF∶CB/VWF∶Ag比值均低于南方O型组(t=7.830,P=0.001;t=2.548,P=0.016),VWF∶Rco差异无统计学意义(P>0.05)。详见表8。
表8

不同地域O型血正常人血浆血管性血友病因子(VWF)水平比较(±s)

组别例数VWF∶Ag(%)VWF∶Rco(%)VWF∶CB(%)VWF∶Rco/VWF∶AgVWF∶CB/VWF∶Ag
北方8145.4±68.0117.2±37.2106.1±32.00.84±0.090.77±0.09
南方2671.2±27.390.9±34.268.4±17.21.28±0.151.04±0.30

t4.6001.8644.3707.8302.548
P0.0010.0710.0010.0010.016

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验 9.不同地域非O型血正常人血浆VWF水平比较:北方非O型血组VWF∶Rco/VWF∶Ag和VWF∶CB/VWF∶Ag比值均低于南方非O型血组(t=4.148,P=0.001;t=3.226,P=0.003),VWF∶Ag、VWF∶Rco、VWF∶CB差异均无统计学意义(P>0.05)。详见表9。
表9

不同地域非O型血正常人血浆血管性血友病因子(VWF)水平比较(±s)

组别例数VWF∶Ag(%)VWF∶Rco(%)VWF∶CB(%)VWF∶Rco/VWF∶AgVWF∶CB/VWF∶Ag
北方23110.4±41.2112.1±33.399.6±24.61.07±0.250.97±0.27
南方1386.4±28.0118.1±33.6105.2±26.31.39±0.171.26±0.23

t1.8670.5130.6414.1483.226
P0.0710.6110.5260.0010.003

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验 10.北方与南方男性正常人VWF水平比较:北方男性正常人VWF∶Ag、VWF∶CB均高于南方男性(t=3.672,P=0.001;t=2.864,P=0.007),VWF∶Rco/VWF∶Ag比值低于南方男性(t=4.712,P=0.001),VWF∶Rco、VWF∶CB/VWF∶Ag比值差异无统计学意义(P>0.05)。详见表10。
表10

不同地域男性正常人血浆血管性血友病因子(VWF)水平比较(±s)

组别例数VWF∶Ag(%)VWF∶Rco(%)VWF∶CB(%)VWF∶Rco/VWF∶AgVWF∶CB/VWF∶Ag
北方12124.9±46.3116.7±39.1101.2±28.70.97±0.240.86±0.24
南方2377.4±30.299.0±36.375.6±23.11.29±0.161.05±0.30

t3.6721.3352.8644.7121.846
P0.0010.1910.0070.0010.074

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验 11.北方女性组与南方女性组VWF水平比较:北方女性组VWF∶Ag高于南方女性组(t=2.795,P=0.009),VWF∶Rco/VWF∶Ag、VWF∶CB/VWF∶Ag比值低于南方女性组(t=4.439,P=0.001;t=2.842,P=0.008),两组间VWF∶Rco、VWF∶CB差异无统计学意义(P>0.05)。详见表11。
表11

不同地域女性正常人血浆VWF水平比较(±s)

组别例数VWF∶Ag(%)VWF∶Rco(%)VWF∶CB(%)VWF∶Rco/VWF∶AgVWF∶CB/VWF∶Ag
北方19116.0±54.2111.4±30.9101.3±25.51.03±0.240.96±0.26
南方1674.7±25.6101.4±36.688.0±30.81.35±0.171.21±0.26

t2.7950.8761.4004.4392.842
P0.0090.3870.1710.0010.008

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验 12.标准血浆的检测结果及诊断:8份标准血浆样本VWF各项检测结果见表12。标准血浆VWF多聚体分析结果见图1。根据ISTH-SSC VWD委员会推荐标准,可以根据上述指标做出VWD分型诊断。
表12

8份标准血浆血管性血友病因子(VWF)检测及诊断结果

样本号VWF∶Ag(%)VWF∶Rco(%)VWF∶CB(%)FⅧ∶C(%)VWF∶Rco/VWF∶AgVWF∶CB/VWF∶AgFⅧ∶C/VWF∶AgVWF多聚体分析分型
15.21.92.312.50.370.442.40正常2M
246.552.842.054.61.140.901.17正常正常
323.724.022.712.31.010.960.52正常2N
421.99.14.922.10.420.221.01大分子量VWF多聚体缺失2B
566.471.957.067.51.080.861.02正常正常
652.753.3140.717.61.012.670.33正常2N
715.08.38.022.80.550.531.52正常2M
814.71.70.717.60.120.051.20大中分子量VWF多聚体缺失2A

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

图1

8份标准血浆样本血管性血友病因子(VWF)多聚体分析(琼脂糖凝胶垂直电泳法)

1、7:2M型VWD;2、5:正常人;3、6:2N 型VWD;4:2B 型VWD;8:2A型血管性血友病(VWD);9:正常对照

注:VWF∶Ag:VWF抗原;VWF∶Rco:血浆VWF瑞斯托霉素辅因子活性;VWF∶CB:VWF胶原结合试验

8份标准血浆样本血管性血友病因子(VWF)多聚体分析(琼脂糖凝胶垂直电泳法)

1、7:2M型VWD;2、5:正常人;3、6:2N 型VWD;4:2B 型VWD;8:2A型血管性血友病(VWD);9:正常对照

讨论

VWD是最常见的遗传性出血性疾病,是由VWF或相关基因突变导致的VWF数量和质量异常所致[8]。目前国内VWD的实验检测和临床诊断仍存在一定困难,主要原因有:VWD患者临床表现具有较大异质性、国内大多医院实验技术受限而缺乏完善的确诊手段、医患双方对VWD的认识不足。因而积极提升VWF检测能力对提高我国VWD的诊治水平显得极为重要。以往采用的以酶联免疫技术和以固定血小板为基础的VWF抗原和活性测定方法操作繁琐,可重复性及时效性差,难以推广。我们采用的这套全自动VWF检测设备能够测定多项VWF抗原和活性指标,并具有较高的准确性和可靠性,为临床VWD诊断和分型提供了有效手段。 目前国内尚无健康国人VWF∶Ag和活性正常值水平的资料,本研究选择70名健康正常人,在性别、年龄、血型等方面基本匹配。结果发现本组正常人血浆VWF∶Ag为(95.4±44.9)%,VWF∶Rco为(105.9±35.4)%,VWF∶CB为(89.8±28.4)%;有多名受试者上述指标>30%~50%,但未发现<30%者。这一发现与ISTH-SSC有关VWD诊断标准和我国VWD诊疗专家共识一致,即以VWF指标<30%作为VWD诊断阈值。部分正常人VWF测定值可位于30%~50%区间,需仔细鉴别。VWF∶Ag与活性的比值是VWD分型诊断的主要指标,并以<0.6作为2型VWD的分型诊断阈值。本组正常人VWF∶Rco/VWF∶Ag比值为1.18±0.25,VWF∶CB/VWF∶Ag比值为1.03±0.29。虽有3名受试者VWF∶CB/VWF∶Ag比值<0.6,但无VWF∶Rco/VWF∶Ag比值<0.6者。根据本组资料,我们也支持在国内将VWF抗原与活性比值<0.6作为2型VWD的分型诊断阈值,仍以VWF∶Rco/VWF∶Ag比值作为参照为佳。 正常人血循环中VWF水平随着年龄的增长而升高,成年人血浆VWF水平每年增加1%~2%[9],升高的速度随着年龄的增长越来越快[10]。本研究中年龄≥30岁组正常人血浆VWF水平较<30组差异无统计学意义,可能与病例数及分组方法有关。 ABO血型是影响血浆VWF水平最主要的遗传因素。既往有研究表明,O型血人群VWF∶Ag、VWF∶Rco及VWF∶CB水平低于非O型血人群[11]–[12]。本组资料也证明了ABO血型对正常人血浆VWF指标有显著影响。O型血正常人血浆VWF∶Ag水平与非O型血差异无统计学意义,但VWF∶Rco及VWF∶CB水平低于非O型血正常人(P<0.05)。这提示O型血者由于VWF糖基化的差异,除影响到VWF∶Ag水平外,也在一定程度上影响了其功能状态。Emmanuel等[13]报道O型血与非O型血人群的VWF∶Rco/VWF∶Ag及VWF∶CB/VWF∶Ag比值差异无统计学意义,本研究结果与上述文献结果一致。 VWF水平的性别差异与种族有关。白种人血浆VWF水平无性别差异,黑种人女性血浆VWF水平高于男性[14]。本组资料显示健康国人女性与男性血浆VWF抗原与活性水平差异均无统计学意义。另外,我们在本研究中发现北方组VWF∶Ag和VWF∶CB水平高于南方组,而VWF∶Rco/VWF∶Ag和VWF∶CB/VWF∶Ag比值低于南方组。为避免不同地域人群因血型分布差异对结果产生影响,我们比较了不同地域相同血型者VWF检测值的差异,发现北方O型血正常人VWF∶Ag和VWF∶CB明显高于南方O型血正常人,VWF∶Rco也有升高趋势;而北方非O型血者与南方非O型血正常人VWF水平差异无统计学意义。不同地域相同性别比较也发现北方人群较南方正常人血浆VWF各指标有升高趋势,以VWF∶Ag和VWF∶CB水平变化较为显著。 我们使用NIBSC提供的正常人和VWD患者血浆样本并结合VWF多聚体分析数据对本套检测体系在VWD诊断和分型中的效率及准确性进行验证,结果表明,根据VWF∶Rco/VWF∶Ag或VWF∶CB/VWF∶Ag比值、FⅧ∶C/VWF∶Ag比值、是否存在大中分子VWF缺乏可初步作出VWD分型诊断。 总之,我们通过使用全自动、标准化检测仪器首次获得正常人VWF∶Ag、VWF∶Rco、VWF∶CB、FⅧ∶C的检测数据,并比较了不同年龄、ABO血型、性别、地域对健康正常人血浆VWF水平的影响。该方法检测效率较高,可重复性较好,对于提高目前国内VWD实验诊断水平具有重要意义,值得在国内进行推广。
  14 in total

1.  von Willebrand factor: demographics of plasma protein level in a large blood donor cohort from South Wales in the United Kingdom.

Authors:  J A Davies; L S Hathaway; P W Collins; D J Bowen
Journal:  Haemophilia       Date:  2012-03-28       Impact factor: 4.287

2.  Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.

Authors:  Emmanuel J Favaloro; Soma Soltani; Jane McDonald; Ella Grezchnik; Leanne Easton; James W C Favaloro
Journal:  Am J Clin Pathol       Date:  2005-12       Impact factor: 2.493

Review 3.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

Review 4.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

Review 5.  ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?

Authors:  P Vince Jenkins; James S O'Donnell
Journal:  Transfusion       Date:  2006-10       Impact factor: 3.157

6.  Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  M G Conlan; A R Folsom; A Finch; C E Davis; P Sorlie; G Marcucci; K K Wu
Journal:  Thromb Haemost       Date:  1993-09-01       Impact factor: 5.249

7.  The effect of ABO blood group on the diagnosis of von Willebrand disease.

Authors:  J C Gill; J Endres-Brooks; P J Bauer; W J Marks; R R Montgomery
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

8.  An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation.

Authors:  Peter J Lenting; Erik Westein; Virginie Terraube; Anne-Sophie Ribba; Eric G Huizinga; Dominique Meyer; Philip G de Groot; Cécile V Denis
Journal:  J Biol Chem       Date:  2003-11-12       Impact factor: 5.157

9.  Measurement of von Willebrand factor activity: relative effects of ABO blood type and race.

Authors:  C H Miller; E Haff; S J Platt; P Rawlins; C D Drews; A B Dilley; B Evatt
Journal:  J Thromb Haemost       Date:  2003-10       Impact factor: 5.824

10.  Possible race and gender divergence in association of genetic variations with plasma von Willebrand factor: a study of ARIC and 1000 genome cohorts.

Authors:  Zhou Zhou; Fuli Yu; Ashley Buchanan; Yuanyuan Fu; Marco Campos; Kenneth K Wu; Lloyd E Chambless; Aaron R Folsom; Eric Boerwinkle; Jing-fei Dong
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.